Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

doi:10.4251/wjgo.v11.i11.1021

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6600)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

401

WORD

208

HTML

3642

Figures (1-2)

237

Tables (1-4)

178

Sum=4666

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

751

Download

1183

Sum=1934

Nov 15, 2019 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1021-1030
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1021

Full Size Figure Download Figure

Figure 2 Kaplan-Meier curves of progression-free survival and overall survival according to 5-fluorouracil exposure in each treatment group. A, B: progression-free survival in capecitabine group and S-1 group according to 5-fluorouracil exposure; C, D: overall survival analysis in capecitabine group and S-1 group according to 5-fluorouracil exposure.

Citation: Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030
URL: https://www.wjgnet.com/1948-5204/full/v11/i11/1021.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i11.1021